ArticleNature chemical biology2023
A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins.
Abstract read
In one paragraph
Article in Nature chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- DISCO-LAMP: a novel discontinuous LAMP assay for isothermal antigen detection.Sensors & diagnostics · 2026Article
- Structure-Guided Design of Proteomimetics Targeting the SARS-CoV-2 S-RBD/hACE2 Interface.Journal of medicinal chemistry · 2026Article
- Affinity Enhancement in Discrete Multivalent MegaMolecules.Chembiochem : a European journal of chemical biology · 2026Article
- Multivalent Protein Nanorings for Broad and Potent SARS-CoV-2 Neutralization.Advanced healthcare materials · 2026Article
- Rapid selection of high-affinity DARPins using click display.Protein engineering, design & selection : PEDS · 2026Article
- Engineering a Coiled-Coil Protein for DARPin Presentation as a Potent SARS-CoV-2 Therapeutic.Biomacromolecules · 2025Article
- Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants.Biosensors & bioelectronics · 2025Article
- Functional Activity and Binding Specificity of Small Ankyrin Repeat Proteins Called Ankyrons Against SARS-CoV-2 Variants.The AAPS journal · 2025Article
- A modular cell-free protein biosensor platform using split T7 RNA polymerase.Science advances · 2025Article
- A modular cell-free protein biosensor platform using split T7 RNA polymerase.bioRxiv : the preprint server for biology · 2024Article
- Neutralization of SARS-CoV-2 and Intranasal Protection of Mice with a nanoCLAMP Antibody Mimetic.ACS pharmacology & translational science · 2024Article
- Disulfide stabilization reveals conserved dynamic features between SARS-CoV-1 and SARS-CoV-2 spikes.Life science alliance · 2023Article
- Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2.Nature communications · 2023Article
- Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.Molecular aspects of medicine · 2023Review
- Dimeric Ankyrin with Inverted Module Promotes Bifunctional Property in Capturing Capsid to Impede HIV-1 Replication.International journal of molecular sciences · 2023Article
- Targeting SARS-CoV-2 and host cell receptor interactions.Antiviral research · 2023Review
- Respiratory viruses interacting with cells: the importance of electrostatics.Frontiers in microbiology · 2023Review
Corrections and comments
- Update of
Authors and funding
21 authors.
Vikas ChoniraDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, TX, USA.ORCID http://orcid.org/0000-0002-9688-313X
Young D Kwon *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1188-7458
Jason Gorman *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3775-6560
James Brett Case *Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID http://orcid.org/0000-0001-7331-5511
Zhiqiang Ku *Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Rudo SimeonDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, TX, USA.
Ryan G CasnerDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Darcy R HarrisVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Adam S OliaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Tyler StephensVaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Lawrence ShapiroDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Michael F BenderVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Hannah BoydTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0762-0419
I-Ting TengVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Yaroslav TsybovskyVaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-2159-5248
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York City, NY, USA.
Ningyan ZhangTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA. mdiamond@wustl.edu.ORCID http://orcid.org/0000-0002-8791-3165
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. pkwong@mail.nih.gov.ORCID http://orcid.org/0000-0003-3560-232X
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA. zhiqiang.an@uth.tmc.edu.
Zhilei ChenDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, TX, USA. zchen4@tamu.edu.ORCID http://orcid.org/0000-0002-0244-3556
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00017 · NIAID · EMORY UNIVERSITY · PI LOWEN, ANICE · 2021 to 2025
$27.3MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MDesign of Antigenically-Specific Probes for Sera Analysis and MAb IsolationZICAI005111 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2010 to 2025
$4.3MIdentification, structures and ontogenies of SARS-CoV-2 antibodiesZIAAI005147 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2020 to 2025
$2.9MArtificial Ecology Sink as prophylaxis against viral infectionDP2AI136600 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI CHEN, ZHILEI · 2017 to 2017
$2.2MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS 75N93021C00017NIAID NIH HHS DP2 AI136600NIAID NIH HHS R01 AI157155
Abstract
We report the engineering and selection of two synthetic proteins-FSR16m and FSR22-for the possible treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. FSR16m and FSR22 are trimeric proteins composed of DARPin SR16m or SR22 fused with a T4 foldon. Despite selection by a spike protein from a now historical SARS-CoV-2 strain, FSR16m and FSR22 exhibit broad-spectrum neutralization of SARS-CoV-2 strains, inhibiting authentic B.1.351, B.1.617.2 and BA.1.1 viruses, with respective IC
Indexed as
COVID-19SARS-CoV-2AnimalsDesigned Ankyrin Repeat ProteinsHumansMiceMice, TransgenicDesigned Ankyrin Repeat Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.